On the growing complexity of HIV-1 vaccines

HIV Therapy

Volumn 4, Issue 5, 2010, Pages 543-552

  Hanke, Tomáš ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HIV 1 vaccine; human efficacy trial; prime boost; T cell; vaccine complexity

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL PROTECTION; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; PHYLOGENY; REVIEW; T LYMPHOCYTE; VACCINATION; VIRUS REPLICATION;

EID: 78049453433     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.10.40     Document Type: Review

References (117)

1. Barre-Sinoussi F, Chermann JC, Rey F et al.: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220(4599), 868-871 (1983). (Pubitemid 13080157)
2. Markowitz M, Morales-Ramirez JO, Nguyen BY et al.: Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43(5), 509-515 (2006).
3. Tsamis F, Gavrilov S, Kajumo F et al.: Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77(9), 5201-5208 (2003).
4. Walker BD, Burton DR: Toward an AIDS vaccine. Science 320(5877), 760-764 (2008).
5. Global HIV/AIDS Vaccine Enterprise: The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med. 2(2), E25 (2005).
6. Burton DR, Desrosiers RC, Doms RW et al.: HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5(3), 233-236 (2004).
7. Wu X, Yang ZY, Li Y et al.: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329(5993), 856-861 (2010).
8. Hanke T: STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev. Vaccines 7(3), 303-309 (2008).
9. Korber BT, Letvin NL, Haynes BF: T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J. Virol. 83(17), 8300-8314 (2009).
10. McMichael AJ: HIV vaccines. Annu. Rev. Immunol. 24, 227-255 (2006).
11. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312(5779), 1530-1533 (2006).
12. Addo MM, Yu XG, Rathod A et al.: Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77, 2081-2092 (2003).
13. Baalen CA, Guillon C, Baalen MvM et al.: Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. Eur. J. Immunol. 32, 2644-2652 (2002).
14. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75(24), 11983-11991 (2001).
15. Rowland-Jones SL, Pinheiro S, Kaul R et al.: How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? Immunol. Lett. 79(1-2), 15-20 (2001).
16. Zhang D, Shankar P, Xu Z et al.: Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 101(1), 226-235 (2003).
17. + T-cell epitopes. J. Virol. 81(7), 3667-3672 (2007).
18. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13(1), 46-53 (2007).
19. Rolland M, Heckerman D, Deng W et al.: Broad and gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One 3(1), e1424 (2008).
20. Goonetilleke N, Liu MK, Salazar-Gonzalez JF et al.: The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206(6), 1253-1272 (2009).
21. Keele BF, Giorgi EE, Salazar-Gonzalez JF et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105(21), 7552-7557 (2008).
22. Salazar-Gonzalez JF, Salazar MG, Keele BF et al.: Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206(6), 1273-1289 (2009).
23. Gruters RA, van Baalen CA, Osterhaus AD: The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 20, 2011-2015 (2002).
24. + T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 178(5), 2746-2754 (2007).
25. + T cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated major histocompatibility complex class I downregulation. J. Virol. 81(21), 11703-11712 (2007).
26. + T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc. Natl Acad. Sci. USA 106(24), 9791-9796 (2009).
27. Liu J, O'Brien KL, Lynch DM et al.: Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457, 87-91 (2008). In the aftermath of the STEP trial failure, this work demonstrated that a T-cell-based vaccine can partially, substantially protect nonhuman primates against a pathogenic simian immunodeficiency virus (SIV) challenge. This was achieved by a regimen using two serologically distinct adenovirus vectors in a heterologous prime-boost combination expressing SIV Gag.
28. Letourneau S, Im E-J, Mashishi T et al.: Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2, e984 (2007). First publication describing the use of conserved regions (as opposed to conserved CD8 T-cell epitopes) to deal with HIV-1 variability.
29. Rolland M, Nickle DC, Mullins JI: HIV-1 group M conserved elements vaccine. PLoS Pathog. 3(11), e157 (2007).
30. Rosario M, Bridgeman A, Quakkelaar ED et al.: Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur. J. Immunol. 40, 1973-1984 (2010).
31. + CTL activity associated with control of viremia in primary HIV-1 infection. J. Virol. 68, 6103-6110 (1994).
32. Casimiro DR, Wang F, Schleif WA et al.: Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79(24), 15547-15555 (2005).
33. Fellay J, Shianna KV, Ge D et al.: A whole-genome association study of major determinants for host control of HIV-1. Science 317(5840), 944-947 (2007).
34. Fujiwara M, Takiguchi M: HIV-1-specific CTLs effectively suppress replication of HIV-1 in HIV-1-infected macrophages. Blood 109(11), 4832-4838 (2007).
35. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998 (1999).
36. Klenerman P, Wu Y, Phillips R: HIV: current opinion in escapology. Curr. Opin. Microbiol. 5, 408-413 (2002).
37. Koup RA, Safrit JT, Cao Y et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994). (Pubitemid 24183063)
38. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA: Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72(1), 164-169 (1998).
39. O'Brien SJ, Gao X, Carrington M: HLA and AIDS: a cautionary tale. Trends Mol. Med. 7(9), 379-381 (2001).
40. + lymphocytes. Science 283, 857-860 (1999).
41. + T cell expansions driven by vaccination during highly active antiretroviral therapy. J. Immunol. 179(1), 597-606 (2007).
42. + T cell efficacy in vaccination and disease. Nat. Med. 14(6), 623-628 (2008).
43. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC: Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14(6), 617-621 (2008).
44. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204(10), 2473-2485 (2007).
45. Bennett MS, Ng HL, Dagarag M, Ali A, Yang OO: Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J. Virol. 81(10), 4973-4980 (2007).
46. Derby M, Alexander-Miller M, Tse R, Berzofsky J: High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166(3), 1690-1697 (2001).
47. Messaoudi I, Guevara Patino JA, Dyall R, LeMaoult J, Nikolich-Zugich J: Direct link between MHC polymorphism, T cell avidity, and diversity in immune defense. Science 298(5599), 1797-1800 (2002).
48. + T cell populations specific for persistent DNA viruses. J. Exp. Med. 202(10), 1349-1361 (2005).
49. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3(11), 1061-1068 (2002).
50. + T cells. Blood 107(12), 4781-4789 (2006).
51. + T cell responses in SIV infection. J. Exp. Med. 206(4), 923-936 (2009).
52. Harari A, Vallelian F, Pantaleo G: Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur. J. Immunol. 34, 3525-3533 (2004).
53. Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J: Multiple costimulatory modalities enhance CTL avidity. J. Immunol. 174(10), 5994-6004 (2005). (Pubitemid 40663786)
54. Wille-Reece U, Flynn BJ, Lore K et al.: Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203(5), 1249-1258 (2006).
55. Excler JL, Rida W, Priddy F, Fast P, Koff W: A strategy for accelerating the development of preventive AIDS vaccines. AIDS 21(17), 2259-2263 (2007).
56. Hessell AJ, Hangartner L, Hunter M et al.: Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158), 101-104 (2007).
57. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al.: Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009). The first hint of a vaccine efficacy in a Phase IIb human trial. Analysis of the vaccine immunogenicity and a possible identification of correlates of protection are underway.
58. Estcourt MJ, Letourneau S, McMichael AJ, Hanke T: Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. Eur. J. Immunol. 35(9), 2532-2540 (2005).
59. + T cells in mice. J. Clin. Invest. 117(12), 3958-3970 (2007).
60. Sun Y, Santra S, Schmitz JE, Roederer M, Letvin NL: Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys. J. Virol. 82(17), 8812-8819 (2008).
61. Plotkin SA, Orenstein WA, Offit PA: Vaccines. Elsevier (2008).
62. Hansen SG, Vieville C, Whizin N et al.: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15(3), 293-299 (2009).
63. Patterson LJ, Malkevitch N, Venzon D et al.: Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J. Virol. 78(5), 2212-2221 (2004).
64. Bonaldo MC, Martins MA, Rudersdorf R et al.: Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques. J. Virol. 84(7), 3699-3706 (2010).
65. Rose NF, Marx PA, Luckay A et al.: An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106(5), 539-549 (2001).
66. Lorin C, Delebecque F, Labrousse V et al.: A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 23(36), 4463-4472 (2005).
67. Yu W, Fang Q, Zhu W et al.: One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge. Vaccine 28(9), 2088-2096 (2010).
68. Shiver JW, Emini EA: Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355-372 (2004).
69. Thorner AR, Lemckert AA, Goudsmit J et al.: Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J. Virol. 80(24), 12009-12016 (2006).
70. Lasaro MO, Ertl HC: New insights on adenovirus as vaccine vectors. Mol. Ther. 17(8), 1333-1339 (2009).
71. Rosario M, Bridgeman A, Quakkelaar ED et al.: Long peptides induce polyfunctional T cells against conserved regions of HIV with superior breadth to single-gene vaccines in macaques. Eur. J. Immunol. 40(7), 1973-1984 (2010).
72. Both GW, Cameron F, Collins A, Lockett LJ, Shaw J: Production and release testing of ovine atadenovirus vectors. Methods Mol. Med. 130, 69-90 (2007).
73. Bridgeman A, Roshorm Y, Lockett LJ et al.: Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine 28, 474-483 (2010).
74. Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J: Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines 3(4 Suppl.), S75-S88 (2004).
75. Paoletti E, Tartaglia J, Taylor J: Safe and effective poxvirus vectors - NYVAC and ALVAC. Dev. Biol. Stand. 82, 65-69 (1994).
76. Tartaglia J, Perkus ME, Taylor J et al.: NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232 (1992).
77. Im E-J, Hanke T: MVA as a vector for vaccines against HIV-1. Expert Rev. Vaccines 3(4 Suppl. 1), S89-S97 (2004).
78. Greenough TC, Cunningham CK, Muresan P et al.: Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine 26(52), 6883-6893 (2008).
79. Robert-Guroff M: Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol. 18(6), 546-556 (2007).
80. + T cell approach feasible? Nat. Rev. Immunol. 2, 283-291 (2002).
81. Gaschen B, Taylor J, Yusim K et al.: Diversity considerations in HIV-1 vaccine selection. Science 296(5577), 2354-2360 (2002).
82. Lee JK, Stewart-Jones G, Dong T et al.: T cell cross-reactivity and conformational changes during TCR engagement. J. Exp. Med. 200(11), 1455-1466 (2004).
83. Fischer W, Perkins S, Theiler J et al.: Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13(1), 100-106 (2007).
84. + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 16(3), 324-328 (2010).
85. Barouch DH, O'Brien KL, Simmons NL et al.: Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16(3), 319-323 (2010). Important publication describing the broad T-cell immunogenicity of mosaic protein immunogens in rhesus macaques.
86. Blay WM, Gnanakaran S, Foley B, Doria-Rose NA, Korber BT, Haigwood NL: Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques. J. Virol. 80(2), 999-1014 (2006).
87. Gao F, Korber BT, Weaver E, Liao HX, Hahn BH, Haynes BF: Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev. Vaccines 3(4 Suppl.), S161-S168 (2004).
88. Gao F, Weaver EA, Lu Z et al.: Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J. Virol. 79(2), 1154-1163 (2005).
89. Haigwood NL: Update on animal models for HIV research. Eur. J. Immunol. 39(8), 1994-1999 (2009).
90. Wilson NA, Watkins DI: Is an HIV vaccine possible? Braz. J. Infect. Dis. 13(4), 304-310 (2009).
91. Valentine LE, Watkins DI: Relevance of studying T cell responses in SIV-infected rhesus macaques. Trends Microbiol. 16(12), 605-611 (2008).
92. Hu SL: Non-human primate models for AIDS vaccine research. Curr. Drug Targets Infect. Disord. 5(2), 193-201 (2005).
93. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191(5), 654-665 (2005).
94. Pitisuttithum P, Gilbert P, Gurwith M et al.: Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194(12), 1661-1671 (2006).
95. Buchbinder SP, Mehrotra DV, Duerr A et al.: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
96. McElrath MJ, De Rosa SC, Moodie Z et al.: HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372(9653), 1894-1905 (2008).
97. Kibuuka H, Kimutai R, Maboko L et al.: A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J. Infect. Dis. 201(4), 600-607 (2010).
98. Amara RR, Villinger F, Altman JD et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA Vaccine. Science 292, 69-74 (2001).
99. Barouch DH, McKay PF, Sumida SM et al.: Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J. Virol. 77(16), 8729-8735 (2003).
100. Barouch DH, Pau MG, Custers JH et al.: Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172(10), 6290-6297 (2004).
101. Hanke T, Goonetilleke N, McMichael AJ, Dorrell L: Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J. Gen. Virol. 88, 1-12 (2007).
102. Lin J, Calcedo R, Vandenberghe LH, Figueredo JM, Wilson JM: Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum. Gene Ther. 19(7), 663-669 (2008).
103. Rosario M, Hopkins R, Fulkerson J et al.: Novel recombinant BCG, ovine atadenovirus and modified vaccinia virus Ankara vaccines combine to induce robust polyfunctional human immunodeficiency virus-specific CD4 and CD8 T cell responses in rhesus macaques. J. Virol. 84, (2010) (In press).
104. Hanke T, Barnfield C, Wee EG-T et al.: Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J. Gen. Virol. 84, 361-368 (2003).
105. Hanke T, McMichael AJ: Design and construction of an experimental HIV-1 vaccine for a year - 2000 clinical trial in Kenya. Nat. Med. 6, 951-955 (2000).
106. Takahashi H, Cohen J, Hosmalin A et al.: An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA, 85, 3105-3109 (1988).
107. Miller MD, Yamamoto H, Hughes AL, Watkins DI, Letvin NL: Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J. Immunol. 147, 320-329 (1991).
108. Nordstrom EK, Forsell MN, Barnfield C et al.: Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J. Gen. Virol. 86(Pt 2), 349-354 (2005).
109. Im EJ, Saubi N, Virgili G et al.: Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J. Virol. 81(17), 9408-9418 (2007).
110. Larke N, Murphy A, Wirblich C et al.: Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen. J. Virol. 79(23), 14822-14833 (2005).
111. Rosario M, Hopkins R, Fulkerson J et al.: Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J. Virol. 84, 5898-5908 (2010).
112. Kenter GG, Welters MJ, Valentijn AR et al.: Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361(19), 1838-1847 (2009).
113. Wei CH, Sherman LA: N-terminal trimer extension of nominal CD8 T cell epitopes is sufficient to promote cross-presentation to cognate CD8 T cells in vivo. J. Immunol. 179(12), 8280-8286 (2007).
114. Douek DC, Betts MR, Brenchley JM et al.: A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J. Immunol. 168(6), 3099-3104 (2002).
115. UNAIDS: Joint United Nations Programme on HIV/AIDS www.unaids.org
116. IAVI: International AIDS Vaccine Initiative www.iavi.org
117. HVTN: HIV Vaccine Trials Network www.hvtn.org